On May 28, 2020, Vaxxas announced that Merck had exercised its option to utilize Vaxxasﾒ proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate. Merck also retained an option to license the HD-MAP technology for two additional vaccines.